Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PEPG with free AI briefings, catalyst countdowns, and dilution alerts.

PEPG · PepGen Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$104.8M Cash on Hand
21.7mo Cash Runway
Follow PEPG by email Get an email when PEPG reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PEPG, unsubscribe in one click. Privacy

📣 What PEPG Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
PGN-EDO51 Duchenne Muscular Dystrophy Phase 2 · NCT06079736 Terminated
PGN-EDODM1 Myotonic Dystrophy 1 Phase 2 · NCT07220603 Recruiting
PGN-EDODM1 for infusion Myotonic Dystrophy 1 Phase 1 · NCT06204809 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PEPG holds $104.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $14.5M/quarter from operations, an estimated runway of 21.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 18 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PEPG files for a raise →

👥 Who Owns PEPG

Insiders 8.3% Other 5%+ holders 5% Institutions (102 holders) 60.4% Public and other holders 26.3%
HolderTypeShares% of sharesAs of
Oxford Science Enterprises plc
Former 10% Owner
Insider 4,955,388 7.15% 2025-09-30
Commodore Capital LP Institution (13G, 5%+) 4,475,000 6.46% 2026-03-31
VIKING GLOBAL INVESTORS LP 5%+ holder (13G) 3,482,434 5.03% 2026-03-31
James G McArthur
President and CEO, Director · +1.85M options
Insider 296,326 0.43% 2026-03-04
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +50,000 options
Insider 207,672 0.30% 2025-09-26
Noel Donnelly
Chief Financial Officer · +960,376 options
Insider 111,603 0.16% 2026-03-04
Paul Streck
EVP, Head of R&D · +439,316 options
Insider 76,226 0.11% 2026-03-04
Joseph Vittiglio
Chief Business & Legal Officer · +280,000 options
Insider 65,717 0.09% 2026-03-01
Kasra Kasraian
Chief Technical Officer · +210,000 options
Insider 50,074 0.07% 2026-05-21
Mary Beth DeLena
General Counsel · +60,000 options
Insider 14,968 0.02% 2025-03-03

Share count 69,261,282 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PEPG picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PEPG and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.